Abstract
Radiosensitizers labelled with nuclides which emit gamma rays have been proposed to have clinical value in the detection of radioresistant hypoxic cell populations in tumors [1]. Such a diagnostic procedure would be of value for radiation and/or chemotherapy treatment planning in oncology, and could aid the study and treatment of ischemic tissue in the myocardium and in the brain. However, the sensitizers 4-[82Br]-bromomisonidazole (BrMISO) [2] and l-[2-(2-[131I]iodophenoxy)-ethyl]-2-nitroimidazole (IPENI) [3] failed to undergo selective uptake in experimental tumor models. In both cases, and especially with IPENI, the test substances were more lipophilic than hypoxic cell markers used previously [4]. Recent efforts with tritiated misonidazole to label hypoxic cell fractions in human tumors have provided clinical data which support the concept that hypoxic cells may be detected by scintigraphic methods [5].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chapman JD, Franko AJ, Sharplin J (1984) A marker for hypoxic cells in tumors with potential clinical applicability. Br J Cancer 43:546
Jette DC, Wiebe LI, Chapman JD (1983) Synthesis and in vivo distribution and metabolism of the radiosensitizer 4-(82Br) bromomisonidazole in tumor-bearing and normal mice. Int J Nucl Med Biol 10:205–210
Wiebe LI, Jette DC, Chapman JD (1984) Electron-affinic compounds for labelling hypoxic cells: the synthesis and characterization of 1-[2-(2-iodophenoxy)-ethyl]-2-nitroimidazole. Nuklearmedizin 2:63–67
Chapman JD, Baer K, Lee J (1983) Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43:1523–1528
Chapman JD et al. Unpublished work in progress
Jette DC, Wiebe LI, Lee J, Flanagan RJ, Chapman JD (in press) Iodoazomycin riboside [1- (5′-iodo-5′-deoxyribofuranosyl)-2-nitroimidazole], a hypoxic cell marker. 1. In vitro characterization. Rad Res
Jarvis SM, Chapman JD, Ngan-Lee J, Rutledge KA, Barr PJ, Paterson ARP (1982) Azomycin riboside, a sugar homologue of misonidazole with favorable radiosensitizing properties. Cancer Res 42:4358–4363
Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695–712
Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD (1985) The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinoma. J Urol 134
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wiebe, L.I., Jette, D.C., Chapman, J.D., Flanagan, R.J., Meeker, B.E. (1986). Iodoazomycin Riboside [l-(5′-iodo-5′- deoxyribofuranosyl)-2-nitroimidazolel, a Hypoxic Cell Marker In Vivo Evaluation in Experimental Tumors. In: Winkler, C. (eds) Nuclear Medicine in Clinical Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70947-0_59
Download citation
DOI: https://doi.org/10.1007/978-3-642-70947-0_59
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-16164-6
Online ISBN: 978-3-642-70947-0
eBook Packages: Springer Book Archive